信达生物:2026年第三季度产品收入超47亿元 同比增长超40%

格隆汇
12 hours ago
信达生物早间公告, 2026 年第三季度,本公司业务延续强劲增长势头,产品收入超过人民币 47 亿元,同比增长超过 40%,充分印证双轮驱动战略的强劲动能与持续兑现。综合管线重磅新品信尔美 ®(玛仕度肽注射液)、信必乐 ®(托莱西单抗注射液)及信必敏 ®(替妥尤单抗 N01 注射液)市场渗透持续提升;肿瘤产品线中多款酪氨酸激酶抑制剂 (TKI) 产品均实现快速销售增长,共同推动本公司商业化产品组合的整体增长,多元产品矩阵协同发力,驱动收入结构持续优化,增长引擎更加丰富。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10